Evidence map›Paper›PMID 30466219›Full record

ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2018

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.

Changsu Han, Sheng-Min Wang, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Laura Mandelli, Chi-Un Pae, Alessandro Serretti

Erratum issued 2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03952494 nawithdrawnnot on this mapstarted 2022, after this paper: background citation

The myGenes Study:Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2022 to 2023Enrolled0ConditionsDepressionArmsGenomind®Professional PGx Express TM
NCT04923204 completednot on this map

Genetic Variations Associated With the Therapeutic Response and Profile of Adverse Effects in the Treatment of Bipolar Depression

TypeobservationalSponsorAB Biotics, SARan2016 to 2019Enrolled76ConditionsBipolar DisorderArmsPharmacogenomic-testing with NEUROPHARMAGEN
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Major depressive disorder.Nature reviews. Disease primers · 2023
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Changsu HanDepartment of Psychiatry, Korea University College of Medicine, Seoul, Korea.
Sheng-Min WangDepartment of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Won-Myong BahkDepartment of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Soo-Jung LeeDepartment of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ashwin A PatkarDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.
Prakash S MasandGlobal Medical Education, New York, NY, USA.
Laura MandelliDepartment of Biomedical and Neuromotor Sciences, Psychiatric Section, University of Bologna, Bologna, Italy.
Chi-Un PaeDepartment of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Alessandro SerrettiDepartment of Biomedical and Neuromotor Sciences, Psychiatric Section, University of Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance. Methods: An 8-week, randomized, single-blind clinical trial was conducted to evaluate the effectiveness and tolerability of PGATx in 100 patients with MDD. All recruited patients were randomly allocated either to PGATx (n=52) or treatment as usual (TAU, n=48) groups. The primary endpoint was a change of total score of the Hamilton Depression Rating Scale-17 (HAMD-17) from baseline to end of treatment. Response rate (at least 50% reduction in HAMD-17 score from baseline), remission rate (HAMD-17 score ≤7 at the end of treatment) as well as the change of total score of Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER) from baseline to end of treatment were also investigated. Results: The mean change of HAMD-17 score was significantly different between two groups favoring PGATx by -4.1 point of difference ( Conclusion: The present study clearly demonstrate that PGATx may be a better treatment option in the treatment of MDD in terms of effectiveness and tolerability; however, study shortcomings may limit a generalization. Adequately-powered, well-designed, subsequent studies should be mandatory to prove its practicability and clinical utility for routine practice.

Indexed as

AntidepressantsDepressive disorderEffectsPharmacogenetic testingPrecision medicineTolerance

Identifiers

PMID30466219
PMCPMC6245286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.